Merck projects 2026 EPS of $2.66-$2.76 as it raises revenue view to $66.3B-$67.3B following Terns deal (NYSE:MRK)

Merck (MRK) has raised its full-year 2026 revenue guidance to $66.3B–$67.3B and introduced EPS guidance of $2.66–$2.76, signaling confidence in its commercial execution and portfolio strength. This upward revision reflects management's conviction in near-term momentum, particularly around flagship oncology assets and newly acquired pipeline assets.

The Terns Pharmaceuticals acquisition adds meaningful exposure to metabolic disease, a high-growth category where LIPFENDRA and other pipeline candidates represent substantial market opportunities. This strategic move positions Merck to compete more aggressively in obesity and diabetes markets, where demand dynamics and pricing power remain robust through 2026 and beyond.

KEYTRUDA outlook continues to underpin guidance, though the maturing franchise requires offsetting contributions from newer launches and bolt-on acquisitions. The breadth of pipeline catalysts—spanning oncology, cardio-metabolic, and infectious disease—mitigates single-product concentration risk and supports revenue sustainability at elevated levels.

Sector implication: Raised guidance by a large-cap pharmaceutical player typically signals sector-wide confidence in underlying demand, patent protection, and pricing resilience. This bullish posture may support Health Care sector rotation if growth concerns persist elsewhere, though execution risk on integration and competition remain.